UroGen Pharma (URGN) Wells Fargo 21st Annual Healthcare Conference summary

Company overview and recent developments

• Built on proprietary RTGel technology to address unmet needs in urothelial cancers, enabling longer drug dwell time and improved cancer cell eradication.

• Approval and launch of ZUSDURI in non-muscle invasive bladder cancer marked a pivotal shift, expanding from a smaller upper tract indication to a much larger market.

• ZUSDURI's market opportunity is about 60,000 patients annually, ten times larger than the upper tract indication for JELMYTO.

• Focus remains on advancing urothelial cancer treatments and diversifying into other specialty cancers for sustainable growth.

Commercial performance and adoption

• ZUSDURI's adoption accelerated after receiving a permanent J-code, with 450 prescribers and growing repeat usage.

• Shift from hospital-based to community-based practices is driving broader patient access and adoption.

• Key growth indicators include expanding prescriber base and increasing repeat writers, with 45% of prescribers treating multiple patients by Q2.

• Reimbursement confidence and operational readiness at sites are crucial for further adoption.

Competitive landscape and product differentiation

• ZUSDURI holds a first-mover advantage in low-grade, intermediate-risk NMIBC, with no direct competition expected for 2–3 years.

• Offers an 80% complete response and durability rate, with a short, six-week treatment course and no maintenance required, unlike competitors.

• Competitors' drugs are typically adjuvant to surgery and require longer maintenance schedules.